Skip to main content
Top
Published in:

18-12-2024 | Pneumonitis | Original Article

Endoscopic Submucosal Dissection for Recurrent Esophageal Squamous Cell Carcinoma Post-Radiation

Authors: Yasuhiro Inokuchi, Kyoko Furusawa, Kei Hayashi, Shin Maeda

Published in: Digestive Diseases and Sciences | Issue 2/2025

Login to get access

Abstract

Background

The feasibility and outcomes of salvage endoscopic submucosal dissection (ESD) and ESD for metachronous esophageal squamous cell cancer (ESCC) inside the irradiated field are not clear.

Aims

To explore the viability of ESD for ESCC in areas previously exposed to radiation, identify elements hindering successful ESD, assess prognosis, and elucidate considerations for follow-up.

Methods

Patients with ESCC who underwent salvage ESD or ESD for metachronous ESCC within the previously irradiated field at Kanagawa Cancer Center between January 1, 2013, and December 31, 2023, were retrospectively investigated to evaluate patient and lesion characteristics and short- and long-term outcomes.

Results

Thirty patients with 41 lesions were analyzed. The median age was 73 (52–88), and 93.3% were men. The middle thorax was the primary location, with flat lesions constituting 73.2%. In salvage ESD cases, the en bloc dissection rate was 91.3%, without adverse events. Conversely, the en bloc dissection rate in metachronous ESD was 100%, and aspiration pneumonitis and post-procedure stricture occurred in 12.5% and 12.5%, respectively. No lesion removed by salvage ESD recurred. During a median follow-up period of 685 (range 24–3061) days, 10 patients (52.6%) developed other organ malignancies, three died from pneumonia, and one died from pharyngeal cancer. The 5-year overall survival rate was 74.9%. No patient died of esophageal cancer.

Conclusions

Salvage and metachronous ESD are feasible and can achieve high en bloc resection rates and good local control. Screening for other organ malignancies after salvage ESD is indispensable. Preventing aspiration may also improve the prognosis.

Graphical Abstract

Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249.PubMed Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249.PubMed
2.
go back to reference Kitagawa Y, Ishihara R, Ishikawa H et al. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1. Esophagus. 2023;20:343–372.PubMedPubMedCentral Kitagawa Y, Ishihara R, Ishikawa H et al. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1. Esophagus. 2023;20:343–372.PubMedPubMedCentral
3.
go back to reference Yagi K, Toriumi T, Aikou S, Yamashita H, Seto Y. Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Ann Gastroenterol Surg. 2021;5:436–445.PubMedPubMedCentral Yagi K, Toriumi T, Aikou S, Yamashita H, Seto Y. Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Ann Gastroenterol Surg. 2021;5:436–445.PubMedPubMedCentral
4.
go back to reference Chen Y, Lu Y, Wang Y et al. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone: Salvage therapy for recurrent ESCC. Dis Esophagus. 2014;27:134–140.PubMed Chen Y, Lu Y, Wang Y et al. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone: Salvage therapy for recurrent ESCC. Dis Esophagus. 2014;27:134–140.PubMed
5.
go back to reference Tachimori Y, Kanamori N, Uemura N, Hokamura N, Igaki H, Kato H. Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2009;137:49–54.PubMed Tachimori Y, Kanamori N, Uemura N, Hokamura N, Igaki H, Kato H. Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2009;137:49–54.PubMed
6.
go back to reference Takeuchi H, Saikawa Y, Oyama T et al. Factors influencing the long-term survival in patients with esophageal cancer who underwent esophagectomy after chemoradiotherapy. World J Surg. 2010;34:277–284.PubMed Takeuchi H, Saikawa Y, Oyama T et al. Factors influencing the long-term survival in patients with esophageal cancer who underwent esophagectomy after chemoradiotherapy. World J Surg. 2010;34:277–284.PubMed
7.
go back to reference Hayami M, Watanabe M, Ishizuka N et al. Prognostic impact of postoperative pulmonary complications following salvage esophagectomy after definitive chemoradiotherapy. J Surg Oncol. 2018;117:1251–1259.PubMed Hayami M, Watanabe M, Ishizuka N et al. Prognostic impact of postoperative pulmonary complications following salvage esophagectomy after definitive chemoradiotherapy. J Surg Oncol. 2018;117:1251–1259.PubMed
8.
go back to reference Cohen C, Tessier W, Gronnier C et al. Salvage surgery for esophageal cancer: How to improve outcomes? Ann Surg Oncol. 2018;25:1277–1286.PubMed Cohen C, Tessier W, Gronnier C et al. Salvage surgery for esophageal cancer: How to improve outcomes? Ann Surg Oncol. 2018;25:1277–1286.PubMed
9.
go back to reference Kiyozumi Y, Yoshida N, Ishimoto T et al. Prognostic factors of salvage esophagectomy for residual or recurrent esophageal squamous cell carcinoma after definitive chemoradiotherapy. World J Surg. 2018;42:2887–2893.PubMed Kiyozumi Y, Yoshida N, Ishimoto T et al. Prognostic factors of salvage esophagectomy for residual or recurrent esophageal squamous cell carcinoma after definitive chemoradiotherapy. World J Surg. 2018;42:2887–2893.PubMed
10.
go back to reference Mitchell KG, Nelson DB, Corsini EM, et al. Morbidity following salvage esophagectomy for squamous cell carcinoma: the MD Anderson experience. Dis Esophagus. 2020;33. Mitchell KG, Nelson DB, Corsini EM, et al. Morbidity following salvage esophagectomy for squamous cell carcinoma: the MD Anderson experience. Dis Esophagus. 2020;33.
11.
go back to reference Sugimura K, Miyata H, Shinno N et al. Prognostic impact of postoperative complications following salvage esophagectomy for esophageal cancer after definitive chemoradiotherapy. Oncology. 2020;98:280–288.PubMed Sugimura K, Miyata H, Shinno N et al. Prognostic impact of postoperative complications following salvage esophagectomy for esophageal cancer after definitive chemoradiotherapy. Oncology. 2020;98:280–288.PubMed
12.
go back to reference Noordman BJ, de Bekker-Grob EW, Coene PPLO et al. Patients’ preferences for treatment after neoadjuvant chemoradiotherapy for oesophageal cancer: Patients’ preferences for treatment after chemoradiation for oesophageal cancer. Br J Surg. 2018;105:1630–1638.PubMed Noordman BJ, de Bekker-Grob EW, Coene PPLO et al. Patients’ preferences for treatment after neoadjuvant chemoradiotherapy for oesophageal cancer: Patients’ preferences for treatment after chemoradiation for oesophageal cancer. Br J Surg. 2018;105:1630–1638.PubMed
13.
go back to reference Hatogai K, Yano T, Kojima T et al. Salvage photodynamic therapy for local failure after chemoradiotherapy for esophageal squamous cell carcinoma. Gastrointest Endosc. 2016;83:1130-1139.e3.PubMed Hatogai K, Yano T, Kojima T et al. Salvage photodynamic therapy for local failure after chemoradiotherapy for esophageal squamous cell carcinoma. Gastrointest Endosc. 2016;83:1130-1139.e3.PubMed
14.
go back to reference Yano T, Muto M, Hattori S et al. Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy. 2008;40:717–721.PubMed Yano T, Muto M, Hattori S et al. Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy. 2008;40:717–721.PubMed
15.
go back to reference Kagawa T, Ishikawa S, Inaba T et al. Clinicopathological examination of ESD as salvage therapy for esophageal cancer after definitive chemo-radiation therapy. Endosc Int Open. 2018;6:E450–E461.PubMedPubMedCentral Kagawa T, Ishikawa S, Inaba T et al. Clinicopathological examination of ESD as salvage therapy for esophageal cancer after definitive chemo-radiation therapy. Endosc Int Open. 2018;6:E450–E461.PubMedPubMedCentral
16.
go back to reference Nagai Y, Yoshida N, Baba H. Salvage treatment for superficial local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Dig Endosc. 2020;32:146.PubMed Nagai Y, Yoshida N, Baba H. Salvage treatment for superficial local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Dig Endosc. 2020;32:146.PubMed
17.
go back to reference Kimura H, Yoshida M, Yabuuchi Y et al. Long-term outcomes of salvage endoscopic submucosal dissection for local failure after chemoradiotherapy for esophageal squamous cell carcinoma. Jpn J Clin Oncol. 2021;51:1036–1043.PubMed Kimura H, Yoshida M, Yabuuchi Y et al. Long-term outcomes of salvage endoscopic submucosal dissection for local failure after chemoradiotherapy for esophageal squamous cell carcinoma. Jpn J Clin Oncol. 2021;51:1036–1043.PubMed
18.
go back to reference Nakajo K, Yoda Y, Hori K et al. Technical feasibility of endoscopic submucosal dissection for local failure after chemoradiotherapy or radiotherapy for esophageal squamous cell carcinoma. Gastrointest Endosc. 2018;88:637–646.PubMed Nakajo K, Yoda Y, Hori K et al. Technical feasibility of endoscopic submucosal dissection for local failure after chemoradiotherapy or radiotherapy for esophageal squamous cell carcinoma. Gastrointest Endosc. 2018;88:637–646.PubMed
19.
go back to reference Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655.PubMed Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655.PubMed
20.
go back to reference Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–458.PubMed Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–458.PubMed
21.
go back to reference Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev. 2006;CD002092. Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev. 2006;CD002092.
22.
go back to reference Kato H, Sato A, Fukuda H et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. 2009;39:638–643.PubMed Kato H, Sato A, Fukuda H et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. 2009;39:638–643.PubMed
23.
go back to reference Kato K, Muro K, Minashi K et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011;81:684–690.PubMed Kato K, Muro K, Minashi K et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011;81:684–690.PubMed
24.
go back to reference Sudo K, Kato K, Kuwabara H et al. Patterns of relapse after definitive chemoradiotherapy in stage II/III (non-T4) esophageal squamous cell carcinoma. Oncology. 2018;94:47–54.PubMed Sudo K, Kato K, Kuwabara H et al. Patterns of relapse after definitive chemoradiotherapy in stage II/III (non-T4) esophageal squamous cell carcinoma. Oncology. 2018;94:47–54.PubMed
25.
go back to reference Ohtsu A, Boku N, Muro K et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–2921.PubMed Ohtsu A, Boku N, Muro K et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–2921.PubMed
26.
go back to reference Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol. 2004;34:615–619.PubMed Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol. 2004;34:615–619.PubMed
27.
go back to reference Versteijne E, van Laarhoven HWM, van Hooft JE et al. Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: locoregional recurrence pattern: DCRT oesophageal cancer: recurrence pattern. Dis Esophagus. 2015;28:453–459.PubMed Versteijne E, van Laarhoven HWM, van Hooft JE et al. Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: locoregional recurrence pattern: DCRT oesophageal cancer: recurrence pattern. Dis Esophagus. 2015;28:453–459.PubMed
28.
go back to reference Takeuchi H, Ito Y, Machida R et al. A single-arm confirmatory study of definitive chemoradiation therapy including salvage treatment for clinical stage II/III esophageal squamous cell carcinoma (JCOG0909 study). Int J Radiat Oncol Biol Phys. 2022;114:454–462.PubMed Takeuchi H, Ito Y, Machida R et al. A single-arm confirmatory study of definitive chemoradiation therapy including salvage treatment for clinical stage II/III esophageal squamous cell carcinoma (JCOG0909 study). Int J Radiat Oncol Biol Phys. 2022;114:454–462.PubMed
29.
go back to reference Takeuchi M, Kobayashi M, Hashimoto S et al. Salvage endoscopic submucosal dissection in patients with local failure after chemoradiotherapy for esophageal squamous cell carcinoma. Scand J Gastroenterol. 2013;48:1095–1101.PubMed Takeuchi M, Kobayashi M, Hashimoto S et al. Salvage endoscopic submucosal dissection in patients with local failure after chemoradiotherapy for esophageal squamous cell carcinoma. Scand J Gastroenterol. 2013;48:1095–1101.PubMed
30.
go back to reference Koizumi S, Jin M, Matsuhashi T et al. Salvage endoscopic submucosal dissection for the esophagus-localized recurrence of esophageal squamous cell cancer after definitive chemoradiotherapy. Gastrointest Endosc. 2014;79:348–353.PubMed Koizumi S, Jin M, Matsuhashi T et al. Salvage endoscopic submucosal dissection for the esophagus-localized recurrence of esophageal squamous cell cancer after definitive chemoradiotherapy. Gastrointest Endosc. 2014;79:348–353.PubMed
31.
go back to reference Makazu M, Kato K, Takisawa H et al. Feasibility of endoscopic mucosal resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage IB, II, and III esophageal squamous cell cancer: Salvage EMR for esophageal cancer. Dis Esophagus. 2014;27:42–49.PubMed Makazu M, Kato K, Takisawa H et al. Feasibility of endoscopic mucosal resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage IB, II, and III esophageal squamous cell cancer: Salvage EMR for esophageal cancer. Dis Esophagus. 2014;27:42–49.PubMed
32.
go back to reference Hatogai K, Yano T, Kojima T et al. Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer. Radiat Oncol. 2016;11:31.PubMedPubMedCentral Hatogai K, Yano T, Kojima T et al. Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer. Radiat Oncol. 2016;11:31.PubMedPubMedCentral
33.
go back to reference Kondo S, Tajika M, Tanaka T et al. Prognostic factors for salvage endoscopic resection for esophageal squamous cell carcinoma after chemoradiotherapy or radiotherapy alone. Endosc Int Open. 2016;4:E841–E848.PubMedPubMedCentral Kondo S, Tajika M, Tanaka T et al. Prognostic factors for salvage endoscopic resection for esophageal squamous cell carcinoma after chemoradiotherapy or radiotherapy alone. Endosc Int Open. 2016;4:E841–E848.PubMedPubMedCentral
34.
go back to reference Ego M, Abe S, Nakatani Y et al. Correction to: Long-term outcomes of patients with recurrent squamous cell carcinoma of the esophagus undergoing salvage endoscopic resection after definitive chemoradiotherapy. Surg Endosc. 2021;35:1777.PubMed Ego M, Abe S, Nakatani Y et al. Correction to: Long-term outcomes of patients with recurrent squamous cell carcinoma of the esophagus undergoing salvage endoscopic resection after definitive chemoradiotherapy. Surg Endosc. 2021;35:1777.PubMed
35.
go back to reference Ishii N, Horiki N, Itoh T et al. Endoscopic submucosal dissection with a combination of small-caliber-tip transparent hood and flex knife is a safe and effective treatment for superficial esophageal neoplasias. Surg Endosc. 2010;24:335–342.PubMed Ishii N, Horiki N, Itoh T et al. Endoscopic submucosal dissection with a combination of small-caliber-tip transparent hood and flex knife is a safe and effective treatment for superficial esophageal neoplasias. Surg Endosc. 2010;24:335–342.PubMed
36.
go back to reference Fujiyoshi Y, Shimamura Y, Inoue H. Usefulness of a newly developed distal attachment: Super soft hood (Space adjuster) in therapeutic endoscopy. Dig Endosc. 2020;32:e38–e39.PubMed Fujiyoshi Y, Shimamura Y, Inoue H. Usefulness of a newly developed distal attachment: Super soft hood (Space adjuster) in therapeutic endoscopy. Dig Endosc. 2020;32:e38–e39.PubMed
37.
go back to reference Koike Y, Hirasawa D, Fujita N et al. Usefulness of the thread-traction method in esophageal endoscopic submucosal dissection: randomized controlled trial: Usefulness of thread-traction method. Dig Endosc. 2015;27:303–309.PubMed Koike Y, Hirasawa D, Fujita N et al. Usefulness of the thread-traction method in esophageal endoscopic submucosal dissection: randomized controlled trial: Usefulness of thread-traction method. Dig Endosc. 2015;27:303–309.PubMed
38.
go back to reference Inokuchi Y, Watanabe M, Hayashi K et al. A case of esophageal granular cell tumor diagnosed by mucosal incision-assisted biopsy. Clin J Gastroenterol. 2022;15:53–58.PubMed Inokuchi Y, Watanabe M, Hayashi K et al. A case of esophageal granular cell tumor diagnosed by mucosal incision-assisted biopsy. Clin J Gastroenterol. 2022;15:53–58.PubMed
39.
go back to reference Muramoto T, Sakai E, Ohata K. Thin-endoscope endoscopic submucosal dissection for early esophageal cancer with postoperative stricture. Dig Endosc. 2020;32:e11–e12.PubMed Muramoto T, Sakai E, Ohata K. Thin-endoscope endoscopic submucosal dissection for early esophageal cancer with postoperative stricture. Dig Endosc. 2020;32:e11–e12.PubMed
40.
go back to reference Tanaka S, Toyonaga T, Morita Y. Endoscopic vessel sealing: a novel endoscopic precoagulation technique for blood vessels during endoscopic submucosal dissection. Dig Endosc. 2013;25:341–342.PubMed Tanaka S, Toyonaga T, Morita Y. Endoscopic vessel sealing: a novel endoscopic precoagulation technique for blood vessels during endoscopic submucosal dissection. Dig Endosc. 2013;25:341–342.PubMed
41.
go back to reference Yamamoto S, Ishihara R, Iishi H et al. Endoscopic classification of local recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Esophagus. 2009;6:243–248. Yamamoto S, Ishihara R, Iishi H et al. Endoscopic classification of local recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Esophagus. 2009;6:243–248.
42.
go back to reference Shapiro J, ten Kate FJW, van Hagen P, Biermann K, Wijnhoven BPL, van Lanschot JJB. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa. Ann Surg. 2013;258:678–688 (discussion 688–689).PubMed Shapiro J, ten Kate FJW, van Hagen P, Biermann K, Wijnhoven BPL, van Lanschot JJB. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa. Ann Surg. 2013;258:678–688 (discussion 688–689).PubMed
43.
go back to reference Tu CH, Muto M, Horimatsu T et al. Submucosal tumor appearance is a useful endoscopic predictor of early primary-site recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma: endoscopy for early detection of recurrent esophageal cancer. Dis Esophagus. 2011;24:274–278.PubMed Tu CH, Muto M, Horimatsu T et al. Submucosal tumor appearance is a useful endoscopic predictor of early primary-site recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma: endoscopy for early detection of recurrent esophageal cancer. Dis Esophagus. 2011;24:274–278.PubMed
44.
go back to reference Noordman BJ, Wijnhoven BPL, Lagarde SM et al. Active surveillance in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal or junctional cancer. Dis Esophagus. 2017;30:1–8.PubMed Noordman BJ, Wijnhoven BPL, Lagarde SM et al. Active surveillance in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal or junctional cancer. Dis Esophagus. 2017;30:1–8.PubMed
Metadata
Title
Endoscopic Submucosal Dissection for Recurrent Esophageal Squamous Cell Carcinoma Post-Radiation
Authors
Yasuhiro Inokuchi
Kyoko Furusawa
Kei Hayashi
Shin Maeda
Publication date
18-12-2024
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 2/2025
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-024-08789-9

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now
Video